Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07321886 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Study acronym: ENLIGHTEN-1
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 162 → 158 locations
    • Eligibility criteria expanded, about 20 words
  2. Site details revised at 29 of 162 sitesv14
  3. Site details revised at 3 of 162 sitesv13
  4. Trial sites reduced: 169 → 162 locationsv12
  5. Site details revised at 16 of 169 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. Site details revised at 4 of 169 sitesv10
  2. Study sites: 170 to 169v9
  3. Study sites: 172 to 170v8
  4. Study sites: 173 to 172v7
  5. Site contacts updated at 1 of 173 sitesv6
  6. Study sites revised (173)v5
  7. Site details revised at 4 of 173 sitesv4
  8. Site details revised at 3 of 173 sitesv3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2026 to Feb 6, 2026
    • Study sites revised (173)
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
361 trials monitored
See 16 trials at risk
Obesity
3,876 trials monitored
See 160 trials at risk
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Trial Details
NCT Number NCT07321886
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overweight
Enrollment 1,980 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov